Ubs Group Ag Phathom Pharmaceuticals, Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 71,941 shares of PHAT stock, worth $671,928. This represents 0.0% of its overall portfolio holdings.

Number of Shares

71,941

Previous 43,086 66.97%

Holding current value

$671,928

Previous $443,000 193.45%

% of portfolio

0.0%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$10.25 - $19.5 $295,763 - $562,672	28,855 Added 66.97%	71,941 $1.3 Million
Q2 2024 Aug 13, 2024	SELL	$8.97 - $12.05 $61,327 - $82,385	-6,837 Reduced 13.7%	43,086 $443,000
Q1 2024 May 13, 2024	BUY	$6.21 - $11.05 $65,149 - $115,925	10,491 Added 26.61%	49,923 $530,000
Q4 2023 Feb 09, 2024	BUY	$6.99 - $10.71 $40,066 - $61,389	5,732 Added 17.01%	39,432 $360,000
Q3 2023 Nov 09, 2023	BUY	$10.26 - $15.7 $173,332 - $265,235	16,894 Added 100.52%	33,700 $349,000
Q2 2023 Aug 11, 2023	BUY	$7.28 - $14.32 $122,347 - $240,661	16,806 New	16,806 $240,000
Q4 2022 Feb 08, 2023	BUY	$9.18 - $11.53 $1,533 - $1,925	167 Added 26.59%	795 $8,000
Q3 2022 Nov 10, 2022	BUY	$6.46 - $12.11 $4,056 - $7,605	628 New	628 $7,000
Q1 2022 May 16, 2022	SELL	$11.55 - $20.06 $15,349 - $26,659	-1,329 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$17.83 - $33.15 $23,696 - $44,056	1,329 New	1,329 $26,000
Q3 2021 Nov 15, 2021	SELL	$30.69 - $36.83 $21,452 - $25,744	-699 Closed	0 $0
Q2 2021 Aug 13, 2021	SELL	$32.66 - $39.87 $71,133 - $86,836	-2,178 Reduced 75.7%	699 $24,000
Q1 2021 May 12, 2021	BUY	$33.86 - $48.68 $7,449 - $10,709	220 Added 8.28%	2,877 $108,000
Q4 2020 Feb 11, 2021	BUY	$33.22 - $50.26 $42,621 - $64,483	1,283 Added 93.38%	2,657 $88,000
Q3 2020 Nov 12, 2020	SELL	$29.24 - $40.19 $81,959 - $112,652	-2,803 Reduced 67.11%	1,374 $50,000
Q2 2020 Jul 31, 2020	SELL	$25.06 - $54.6 $56,084 - $122,194	-2,238 Reduced 34.89%	4,177 $137,000
Q1 2020 May 01, 2020	SELL	$24.65 - $42.83 $189,410 - $329,105	-7,684 Reduced 54.5%	6,415 $166,000
Q4 2019 Feb 14, 2020	BUY	$18.59 - $37.67 $262,100 - $531,109	14,099 New	14,099 $439,000

Others Institutions Holding PHAT

# of Institutions

144

Shares Held

73.6M

Call Options Held

42.3K

Put Options Held

45.7K

View Full List

About Phathom Pharmaceuticals, Inc.

Ticker PHAT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,175,200
Market Cap $366M
Description
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...

More about PHAT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account